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Solid Substrate Room-temperature Phosphorescence of
Phenothiazine and Related Compounds
WIWAM D. SAVAGE and RONALD T. PFLAUM
Department of Chemistry, The University of Iowa, Iowa City, Iowa 52242

CATHERINE HINGA HAUSTEIN*
Department of Chemistry, Central College, Pella, Iowa 50219
The room-temperature phosphorescence characteristics of phenothiazine, phenothiazine-based pharmaceuticals, and related compounds
are presented. It was found that substitution onto the parent ring produces little variation in RTP excitation and emission wavelengths,
but electron withdrawing substituents reduce RTP intensity. Procedures for the determination of procaine and promethazine in urine and
clorpromazine in whole blood are presented.
INDEX DESCRIPTORS: phenothiazine(s), procaine, room-temperature phosphorescence, pharmaceutical analysis

Pharmaceuticals belonging to the phenothiazine class are among
the most widely used drugs in medicine today. Clorpromazine (thorazine) and related derivatives have found their major clinical uses as
tranquilizers. Promethazine (Phenergan), one of the first clinically
used phenothiazine derivatives, has found use as a sedative and an
antihistamine. Chlorothiazide, a diuretic, has been used for the treatment of hypertension and congestive heart failure. Procaine, introduced under the trade name Novocain, is primarily used as a local
anesthetic. It has found wide clinical use because of its low toxicity,
which is due to rapid destruction by esterases in the tissues and blood,
preventing the build up of toxic levels.
Procedures for the determination of drugs in biological fluids
typically involve the use of an isolation technique such as extraction
into a non-polar solvent. 1 Methods for the determination of promethazine and chlorpromazine have been discussed in several review
articles 2-4, and include visible and ultraviolet spectrophotometry, fluorescence, thin-layer and paper chromatography, and gas-liquid chromatography.
Chlorothiazide in urine has most commonly been determined by
spectrophotometric methods5,6, however, the method is not specific.
Recently, several phenothiazine drugs have been determined spectrophotometrically. 7 High pressure liquid chromatography has been
used to assay chlorothiazide in blood plasma and urine following
acidification and extraction into ethyl acetate. 8 Several procedures
have been published for detecting procaine and other basic amine
drugs in a blood matrix. These involve an alkaline extraction into ether
or toluene with subsequent analysis by spectrophotometry9, fluorimetry 10, and gas-liquid chromatography. 11 Low temperature phosphorescence has found application in the analysis of procaine and
chlorpromazine. 12- 14
Room temperature phosphorescence (RTP) is an important breakthrough in the study of phosphors because of its simplicity, selectivity,
and sensitivity. RTP studies of procaine is, p-aminobenzoic acid 16 and
diazepam 17 are among the recent applications of RTP to pharmaceutical analysis, however biological and clincial applications for the technique are not prevalent in the literature. This study illustrates the
potential for the anlaysis of such compounds in biological and clinical
samples.

*To whom correspondence should be addressed.

EXPERIMENTAL
Reagents
Ethanolic solutions were prepared from absolute alcohol which was
distilled prior to use, with the first and last 1% being discarded. Stock
solutions of each pharmaceutical were prepared in 60% alcohol. The
inorganic salts were of reagent grade quality. Chlorpromazine HCl,
prochloroperazine edisylate, and trifluoperazine dihydrochloride were
obtained from Smith, Klein, and French Laboratories; chlorprothixene
from Hoffman-LaRoche Inc.; chlorothiazide and perphenazine from
Merck, Sharpe, and Dohme Research Labs; imipramine HCl from
Bolar Pharmaceutical Co.; procaine hydrochloride from Aldrich
Chemical Company; promethazine hydrochloride from Wyeth Institute for Medical Research, and thioridazine HCl from Sandoz Inc..
All were used as received. Phenothiazine, from Aldrich Chemical
Company, was recrystallized from ethanol. Urine for biological work
was obtained from healthy male volunteers. Expired blood plasma and
citrated whole blood were received from The University of Iowa Blood
Bank.
Procedure
All phosphoroscence measurements were made with an AminoBowman spectrophotofluorimeter with a variable speed Aminco phosphoroscope attachment. The system was used without slits except for a
5 millimeter photomultiplier tube slit. A sample support holder was
constructed from brass according to previous diagrams. 18 Air and
moisture were excluded from the sample chamber environment by
flushing the chamber with nitrogen gas which was first passed
through a drying tube containing 15 grams of Mg(C104 ) 2 .
A 1/4 inch (0.625 cm) circle of Schleicher and Schuell 507 filter
paper was cut using a hole punch. If a heavy atom was incorporated
into the sample matrix, it was applied by soaking strips of filter paper
for one minue in one of the following aqueous solutions: 0.2 M CsCl,
0. 5 M Pb (0Ac) 2 , 2 M LiC10 4 , 0. 5 M Ag N0 3 , 2 M NaBr, 2 M Nal,
or 0. 5 M TIE The papers were dried in a desiccator, each tautly
suspended horizontally between two alligator clips. Once dry, support
circles of 1/4 inch were prepared. The sample support was then held
horizontally in an alligator clip and four microliters of the sample
solution were syringed onto the center of the paper circle.
Initial drying was accomplished by placing the sample in the
desiccator for 5 minutes. The dried sample was placed in the RTP
sample holder and into the nitrogen atmosphere of the phosphoroscope. The intensity of the phosphoroscence signal was then obtained
at the wavelengths of excitation and emission which resulted in the
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largest signal intensity and the intensity was recorded once a stable
maximum was achieved. Samples were dried in the sample chamber in
the presence of ultraviolet light with no adverse effects, with the
exception of phenothiazine which gave unstable readings unless it was
dried with the phosphoroscope chopper off. The time required to reach
a stable signal was approximately ten minutes. The blank for each
sample was obtained by applying 4 uL of solvent to a 1/4 inch support
followed by identical treatment as outlined previously.
Limits of detection correspond to the concentration of sample
solution which gave a detectable signal equal to twice the background
blank. The limit of detection in nanograms corresponds to the phosphor concentration times the volume analyzed.
Procedure for Determination of Pharmaceuticals in Whole
Blood and Plasma
Drug samples in citrated blood and plasma were prepared by
pipeting 0. 50 mL of an aqueous stock solution of known concentration
of the drug, 4.0 mL of absolute ethanol, and 0.50 mL of blood or
plasma into a 15 mL Pyrex centrifuge tube. A standard solution was
prepared by placing 0.50 mL stock drug solution, 4.0 mL absolute
ethanol, and 0. 50 mL water into a centrifuge tube. The blank
consisted of 1.0 mL water and 4.0 mL absolute ethanol.
The mixtures were mechanically shaken for 2 minutes, then centrifuged at 8000 rpm for 5 minutes to separate the precipitated
protein. The resultant liquids were applied to filter paper supports and
analyzed for phosphorescence.
Calibration curves were obtained by appropriate dilutions of the
stock solution of approximately 700 - 100 ppm prior to addition of
blood and ethanol.
Procedure for Determination of Pharmaceuticals in Urine
The following solutions were added to a 0.25 mL sample of urine:
0.25 mL of stock solution of the drug to be tested in 60% ethanol,
0. 75 mL of0.01 M pH 5 acetate buffer, and 5.0 mL of ethyl acetate.
After mixing with a wrist action shaker for 10 minutes the sample was
centrifuged at 2000 rpm for 3 minutes. The ethyl acetate layer was
separated, transferred to a clean beaker, and evaporated to dryness at
60° C in a drying oven. One milliliter of water was added to the residue
and this solution was placed on a filter which had been treated with the
appropriate heavy atom. A standard solution was prepared from 0.25
mL stock solution, 0.25 mL acetate buffer, and 5.0 mL ethyl acetate.
The blank consisted of 0.50 mL of water, 0. 75 mL of acetate buffer,
and 5.0 mL of ethyl acetate.
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Fig. 1. Room-temperature phosphorescence spectrum of perphenazine.
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Fig. 2. Room-temperature phosphorescence spectrum of thioridazine.

The percentage of drug found in blood or urine was determined by
dividing the corrected signal intensity (signal minus the blank) of the
biological sample by the corrected signal intensity of the standard
solution.

RESULTS AND DISCUSSION
Table 1 illustrates the structures of the molecules studied and
summarizes the room temperature phosphorescence wavelengths. Experimental factors found to influence phosphorescence of absorbed
pharmaceuticals at room temperature include the choice of paper
support, solvent system, elimination of moisture from the sample
support matrix, and the method of heavy atom application. 19- 21 In our
study, it was found that a very large signal to background ratio was
obtained with Schleicher and Schuell #507, a very smooth, thin
paper. The phosphorescence background for this paper was a broad
continuum with excitation and emission wavelengths around 300 and
500 nm, respectively. The blank intensity appeared to be constant at
specified wavelengths from sample to sample. Heavy atom perturbers,
which increase the sample signals, also increase the background.
Ratios of signal to background ranged from 160-302 for supports with
no heavy atom to 55-254 for heavy atom treated supports.
The phenothiazines had two excitation wavelengths at approximately 263 nm and 325 nm, which corresponded to the two absorption wavelengths noted for these compounds. 22 Only one emission
band, at 525 nm, was observed. There appeared to be little difference
in the excitation and emission wavelengths of phenothiazines with
various substituent groups in the three and ten positions although the
intensity of the excitation peak at 263 nm varied somewhat, as
illustrated by the spectra of perphenazine (Figure 1) and thioridazine
(Figure 2). A study of the photoelectric spectra of these compounds
concluded that 3 and 10 substitutions had little effect on the electronic
character of the aromatic portion of the molecule. 2 3 It follows that the
aromatic portion of phenothiazines is primarily responsible for their
RTP characteristics and this explains the lack of change in the excitation and emission wavelengths. One notable exception was trifluoperazine, which showed a greatly reduced RTP intensity when compared with other phenothiazine pharmaceuticals. The trifluromethane
group is a strong withdrawing group which disrupts the aromaticity of
the molecule. Oxidation of the phenothiazines, by air and/or hydrogen
peroxide, to the sulfoxide or the sulfone also destroys the RTP of the
compounds. Phenoxazine, which contains an oxygen instead of an
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amine group in the phenothiazine ring, also did not phosphoresce,
again indicating that electron withdrawing groups reduce RTP signal
intensities. Other studies with indoles have also supported this observation. 24 Chlorprothixene and imipramine are two tranquilizers with
biological activity similar to the phenothiazine pharmaceuticals, yet
they also did not exhibit room temperature phosphorescence. Both
structures contain unconjugated center rings and this would contribute to their lack of phosphorescence. It is believed that steric, rather
than electronic effects, are responsible for the pharmaceutical action of
these compounds, in particular, conformational similarities with
dopamine. 25
Thianthrene is a phenothiazine like structure containing two sulfur
atoms instead of a sulfur and a nitrogen between the phenyl rings. Like
phenothiazine, thianthrene had an excitation peak at 263 nm, although this was more intense for thianthrene when compared to the
same concentration of phenothiazine, as shown in Figure 3. This
indicates that excitation at 263 nm is primarily due to the sulfur atom
in phenothiazine and like compounds. This is supported by photoelectron data. 23
The stability of heavy atom treated strips was also studied. It was
found that dried strips could be stored in a desiccator for up to two
weeks without compromising reproductibility of the RTP signals (a
relative standard deviation of3%). As well as improving the sensitivity
of detection for many phosphors, heavy atoms can also improve the
selectivity of RTP. Although the RTP of phenothiazine with iodide
perturbation has been reported 2 6, phenothiazine phosphorescences
intensely without heavy atom perturbation. This makes RTP a selective method for the determination of phenothiazine and its derivatives,
since relatively few compounds phosphoresce strongly without heavy
atoms.
A linear relationship exists between RTP intensity and concentration for promethazine over a concentration range of 1.0 - 870 ug/mL,
for chlorothiazide from 3.1-43- 700 ug/mL, and for procaine from
4.2-375 ug/mL.
In any analysis of pharmaceuticals in biological systems, the presence of metabolic products of the drugs must be considered. If the
metabolites of the drug phosphoresce, or if phosphorescent interferences are present, these substances must be removed, unless spectral
resolution of the materials is possible. In the case of chlorothiazide,
absorption from the intestinal tract is rapid. The drug is not metabolized in the kidneys and is excreted in the urine unchanged. The
concentration of the drug is much higher in urine than in plasma. 27
Procaine, however, is hydrolysed in the blood by chlorinesterase and
pseudocholineseterase enzymes, forming p-aminobenzoic acid and
diethylaminoethanol. Of the initial dose, 50-60% is excreted unchanged. Approximately 10% of the procaine is metabolised into
p-aminobenzoic acid and the remainder diethylaminoethanol. 28
The RTP excitation and emission wavelengths of procaine are
within 10-20 nm of those of p-aminobenzoic acid and since RTP
spectra are often broad, spectral resolution of the compounds is
unlikely. However, the RTP of procaine is enhanced by lead acetate or
thallium fluoride, while the use of these heavy atoms quenches the
phosphorescence of p-aminobenzoic acid. Therefore, selective heavy
atom enhancement may be applicable for the analysis of procaine in the
presence of its major metabolite.
Promethazine and procaine were studied to show the application of
room temperature phosphorescence in the determination of pharmaceuticals in whole blood. Thiamine, riboflavin, tyrosine, and tryptophan are phosphorescent compounds which could be potential interferences. To remove these interferences, absolute ethanol was added to
the blood or plasma to cause immediate precipitation of the protein
present. Percent recoveries ranged from 106-102% for promethazine
and 95. 7% to 91.1% for procaine. The procedure allows for excellent
recovery of the pharmaceuticals.
Preliminary study of the pharmaceuticals in urine consisted of
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Fig. 3. Room-temperature phosphorescence spectra of thianthrene and
phenothiazine.
comparing the phosphorescence intensities of promethazine, chlorothiazide, and chlorpromazine in urine to the same concentration in
water. Background urine blanks had essentially no phosphorescence
signals, but the urine matrix reduced the RTP intensities of the
pharmaceuticals tested to 27 .2-62.8% of the intensities of the drugs in
water. Constituents present in urine either interfere with the binding
of the phosphor to the paper, with the interaction of the heavy atoms
with the desired phosphor, or both. However, a 99.1% recovery of
chlorothiazide was obtained following extraction with ethyl acetate.
In conclusion, RTP is a potentially powerful tool for the analysis of
pharmaceuticals. It is a simple, sensitive, and selective analytical
technique. RTP excitation wavelengths of the phenothiazine compounds correlate with absorption and photoelectron data. The potential for utilization of RTP in clinical studies has been shown and as
more clinical analysts become familiar with the technique, room
temperature phosphorescence will take its rightful place as a technique
which compliments fluorimetry.
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